HANGZHOU, China, Sept. 30,
2024 /PRNewswire/ -- Zhejiang Doer Biologics Co.,
Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company
developing innovative biotherapeutics for metabolic diseases and
cancers, today announces that DR10624, its first-in-class (FIC),
tri-specific agonist targeting Fibroblast growth factor 21 receptor
(FGF21R), Glucagon-like peptide-1 receptor (GLP-1R), and Glucagon
receptor (GCGR) has completed the dosing of the first patient in
the Phase 2 study of DR10624 for the treatment of severe
hypertriglyceridemia (SHTG).
The Phase 2 study is a randomized, placebo-controlled,
double-blind study to evaluate the efficacy and safety of three
dose levels of DR10624 in adult SHTG patients, who have mean
fasting triglycerides of greater than or equal to 5.65 mmol/L (500
mg/dL) at screening. A total of 72 participants will be enrolled in
the study.
"DR10624 is a first-in-class long-acting tri-agonist targeting
FGF21R, GLP-1R, and glucagon receptor (GCGR). Developed using Doer
Bio's proprietary MultipleBody® platform technology, DR10624 was
engineered to exhibit balanced activity for metabolic diseases. In
non-clinical studies, DR10624 has demonstrated extraordinary
potency in reducing body weight, lowering triglycerides,
normalizing blood lipids, and improving liver function." said
Yanshan Huang, Ph.D., founder and
Chief Executive Officer of Doer Bio.
"We're excited to announce the dosing of first patient in our
Phase 2 study of DR10624 for the treatment of severe
hypertriglyceridemia. Patients with SHTG, particularly those with
uncontrolled hypertriglyceridemia, face a heightened risk of
developing acute pancreatitis and atherosclerotic cardiovascular
disease (ASCVD). This Phase 2 study is designed to identify the
optimal dose for pivotal Phase 3 clinical trials. We are eager to
advance DR10624 as a potential treatment for patients struggling
with SHTG". commented Yongliang
Fang, Ph.D., Chief Operating Officer of Doer Bio.
More information about the Phase 2 clinical trial is available
at clinicaltrials.gov (NCT06555640)
About Doer Bio
Zhejiang Doer Biologics Co., Ltd. ("Doer Bio") is a clinical
stage biopharmaceutical company that focuses on the discovery and
development of multi-domain based multi-specific biotherapeutics to
address unmet medical need in the field of metabolic diseases and
cancers.
Doer Bio has developed multiple proprietary platform
technologies, including xLONGylation®, MultiBody®, AccuBody®, and
SMART-VHHBody.
For more information about Doer Bio, please visit
www.doerbio.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/doer-biologics-announces-first-patient-dosed-in-phase-2-study-of-dr10624-for-treatment-of-severe-hypertriglyceridemia-302262301.html
SOURCE Zhejiang Doer Biologics Co., Ltd.